Criticaleye recently caught up with Abbas Hussain, President, Emerging Markets at GlaxoSmithKline, to discuss the state of emerging markets and the initial stages of GSK’s low-cost drug plan, a revolutionary scheme set to change the face of the pharmaceutical industry.
Read, watch & listen to some of the latest thought leadership from our Community.
In this report, Criticaleye Partner AlixPartners suggest that 2026 will likely mark a structural turning point for enterprise software, as AI reshapes not only how software is built, but how it is priced,...
This Discussion Paper Feedback Statement by Criticaleye's Advisory Member London Stock Exchange Group has been published following a recent call for input from all stakeholders relating to the future of Lo...
Singtel faces a rapidly changing environment as geopolitics, customer expectations and AI reshape its business. In discussion with Criticaleye Senior Editor Bridgette Hall, Group Chief People & Sustainability Office...
Displaying 1 to 3 of 400
 (002).png "Palo Alto Networks"){kind=logo}
We use cookies to improve your experience. By using our site, you agree to our use of cookies.
